Home › Cancer (all types) › NCT00349830

Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

Development of Novel Serum Markers for Monitoring Response to Anti-Cancer Therapy

Who can join

Ages 18 and older · All sexes · Healthy volunteers welcome

1. Age \> or = 18; for the samples collected under the NIH grant, no subjects below the age of 20 will be enrolled.
2. Prior diagnosis of cancer or suspected of having cancer
3. Karnofsky performance status of greater than 70
4. Standard pretreatment evaluation
5. Signed Stanford University Human Subjects Committee consent

About the study

The purpose of this study is to measure the levels of serum proteins and other biomarkers in cancer patients and in patients suspected of having cancer. We believe that some of these markers may be useful for confirming the diagnosis or for selecting patients for specific types of cancer therapies. These markers may also help to predict response to therapy, relapse after therapy, and survival after therapy.

What is being tested

• blood draw (procedure)

Sponsor: Stanford University · Participants: 2,000 · Started: 2002-01

Contact the study team

• [email protected] [email protected] · Phone: 650-498-7757
• [email protected] · Phone: 650-498-7757

Official record on ClinicalTrials.gov — NCT00349830

Locations in the U.S.

Conditions

• Cancer (all types)

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.